Clene/CLNN

$0.43

2.11%
-
1D1W1MYTD1YMAX

About Clene

Clene Inc. is a clinical-stage biopharmaceutical company. The Company is focused on treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. Its drug candidate, CNM-Au8, is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. Its other products include CNM-ZnAg and CNM-AgZn17. CNM-ZnAg is a spectrum antiviral, antibacterial agent comprised of zinc and silver ions under development to treat infectious disease and to provide immune support for symptom resolution. CNM-AgZn17 is a gel polymer suspension of zinc and silver under development for treatment of infectious diseases and to support wound healing.

Ticker

CLNN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Etherington

Employees

75

Headquarters

Salt lake city, United States
Website
clene.com

Clene Metrics

BasicAdvanced
$54.78M
Market cap
-
P/E ratio
-$0.48
EPS
0.50
Beta
-
Dividend rate

What the Analysts think about Clene

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 5 analysts.
1,062.79% upside
High $7.00
Low $1.00
$0.43
Current price
$5.00
Average price target

Clene Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,400% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$100K
-50%
Net income
$-2.4M
-90.44%
Profit margin
-2,400%
-80.88%

Clene Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 77.78%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.01
-$0.15
-$0.29
-$0.02
-
Expected
-$0.12
-$0.15
-$0.12
-$0.09
-$0.07
Surprise
-91.95%
3.45%
136.05%
-77.78%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Clene stock

Buy or sell Clene stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing